

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Anderson et al.

Appl. No.: 08/

921,060

Series Code ↑

Serial No. ↑

Filed: August 29, 1997

Hon. Commissioner of Patents

Washington, D.C. 20231

Sir:

**REPLY/AMENDMENT/LETTER**

Group Art Unit

1644

Examiner:

R. Schwadron

Atty. Dkt.

P

0275463

1992-30-0029CP2

M#

Client Ref

Appln. Title: Therapeutic Application of Chimeric and  
Radiolabeled Antibodies to Human B  
Lymphocyte Restricted Differentiation  
Antigen for Treatment of B Cell  
Lymphoma

Date: October 30, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

**FEE REQUIREMENTS FOR CLAIMS AS AMENDED****RECEIVED**

## 1. Small Entity claim

- A. ☒ NOT made  
B. ☐ Withdrawn  
C. ☐ made herewith  
D. ☐ made previously

For B & C  
See **Required**  
**Separate Paper**  
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
			TECH CENTER	1600/2900	Lg/Sm
	**minus 0	0	x \$18/\$9 =	+ \$0	103/203
	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
Multiple dependent claim(s) into this application for first application) ..... add			+ \$280/\$140 =	+ \$0	104/204
<input type="checkbox"/> NONE					
and the original due (1 mo) \$110/\$55 = is filed for which the (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (4 mos) \$1,440/\$720 = (5 mos) \$1,960/\$980 =			+ \$0		115/215 116/216 117/217 118/218 128/228
paid since above original due date and subtract			- \$0		
			Extension Fee	+ \$0	
add Rule 20(d) official fee .....			+ \$110/\$55	+ \$0	148/248
Fee under Rule 97 (c), ..... add			+ \$180	+ \$0	126
..... add			+ \$180		126
es 129(a) and 17(r) .....			+ \$740/370	+ \$0	146/246
examination per Rule 129(b) .....			x \$740/370 ea	+ \$0	149/249
tion (RCE) .....			+ \$740/370	+ \$0	1179/1279
				+ \$0	

TOTAL FEE =

\$

**PLEASE CHARGE  
OUR DEP. ACCT**

15. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".  
17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.  
18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003

C#

0275463

M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT **does not authorize** charge of the **issue fee** until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP  
Intellectual Property Group

By Atty: Robin L. Teskin


Reg. No. 35,030

P.O. Box 10500

McLean, VA 22102

Tel: (703) 905-2000

Sig:



Fax:

(703) 905-2500

Tel:

(703) 905-2200

Atty/Sec: RLT/af

**NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments**



RECEIVED  
OCT 31 2002 461  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

\* \* \* \* \*

**PRELIMINARY AMENDMENT**

Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

Prior the examination add the following additional claims.

**IN THE CLAIMS**

23. A method of treating a human patient suffering from B cell lymphoma comprising administering a therapeutically effective amount of a non-radiolabeled chimeric anti-CD20 antibody, wherein said chimeric anti-CD20 antibody when administered by itself at a dosage of 0.4 mg/kg body weight results in nearly complete B cell depletion within about 24 hours post treatment infusion of said chimeric anti-CD20 antibody.

24. A method of inducing B cell depletion in a patient in need of such depletion comprising administering a B cell depleting effective amount of a non-radiolabeled chimeric anti-CD20 antibody, wherein said chimeric anti-CD20 antibody wherein administered by itself at a dosage of 0.4 mg/kg body weight results in merely complete B cell depletion within about 24 hour post treatment infusion of said chimeric anti-CD20 antibody.

25. The method of claim 11 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11.

26. The method of claim 11 wherein said chimeric anti-CD20 antibody contains the variable light sequence corresponding to SEQ ID NO: 7.

27. The method of claim 16 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11.